Dr. David Granville
Professor
Faculty
Faculty of Medicine
University of British Columbia, Vancouver
Dr. Granville is a Professor in UBC's Department of Pathology and Laboratory Medicine. He is currently a Principal Investigator at the ICORD Centre, the UBC Centre for Heart Lung Innovation and the Director of the Wound Healing and Chronic Disease Research Lab, BC Professional Firefighters' Burn and Wound Healing Research Laboratory. He also holds an adjunct appointment at Simon Fraser University.
Throughout his career, Granville has carried lab discoveries through to actual therapies. Early on, his R&D work at QLT Inc. on photodynamic therapy supported the approval of Visudyne in 1999, the first drug treatment for age-related macular degeneration (AMD).
His current research is focused on mechanisms of tissue injury, inflammation and repair and how aging and dysregulated inflammation affect such processes in the context of identifying new therapeutic targets for the treatment of age-related and/or chronic diseases. His recent research has led to the formation of the UBC-spin-off company, viDA Therapeutics, of which he is a co-Founder and Chief Scientific Officer. He collaborates actively with multiple members of the Vision Cluster on this work, advancing a new generation of tools that target the molecular drivers of the disease at their source.